Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $20

Benzinga · 1d ago
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $25 to $20.